Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 8
Navigating New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC
Panelists discuss how the MARIPOSA trial (ASCO 2024) showed improved overall survival (OS) with amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant non–small cell lung cancer (NSCLC), supporting its FDA approval (October 2024). This regimen may become standard of care for select patients, but osimertinib with or without chemo remains vital. The complete response letter (CRL) for subcutaneous amivantamab may delay uptake.
Video Player is loading.
Video content above is prompted by the following:
- Briefly comment on the latest OS data from MARIPOSA andthe recentFDA approval (October 2024) of combination amivantamab and lazertinib as an advancement in the first-line treatment space.
- MARIPOSA Felip E, et al. ASCO 2024. Abs 8504; J&J press release, January 7, 2025
- Should this combination become the new standard of care for first-line treatment for certain patients?
- What is the remaining role for osimertinib with or without chemotherapy?
- How might the recent CRL for subcutaneous amivantamab impact clinical practice over the next year?
